MicroRNA Expression Profiles of Whole Blood in Lung Adenocarcinoma

The association of lung cancer with changes in microRNAs in plasma shown in multiple studies suggests a utility for circulating microRNA biomarkers in non-invasive detection of the disease. We examined if presence of lung cancer is reflected in whole blood microRNA expression as well, possibly because of a systemic response. Locked nucleic acid microarrays were used to quantify the global expression of microRNAs in whole blood of 22 patients with lung adenocarcinoma and 23 controls, ten of whom had a radiographically detected non-cancerous lung nodule and the other 13 were at high risk for developing lung cancer because of a smoking history of >20 pack-years. Cases and controls differed significantly for age with a mean difference of 10.7 years, but not for gender, race, smoking history, blood hemoglobin, platelet count, or white blood cell count. Of 1282 quantified human microRNAs, 395 (31%) were identified as expressed in the study’s subjects, with 96 (24%) differentially expressed between cases and controls. Classification analyses of microRNA expression data were performed using linear kernel support vector machines (SVM) and top-scoring pairs (TSP) methods, and classifiers to identify presence of lung adenocarcinoma were internally cross-validated. In leave-one-out cross-validation, the TSP classifiers had sensitivity and specificity of 91% and 100%, respectively. The values with SVM were both 91%. In a Monte Carlo cross-validation, average sensitivity and specificity values were 86% and 97%, respectively, with TSP, and 88% and 89%, respectively, with SVM. MicroRNAs miR-190b, miR-630, miR-942, and miR-1284 were the most frequent constituents of the classifiers generated during the analyses. These results suggest that whole blood microRNA expression profiles can be used to distinguish lung cancer cases from clinically relevant controls. Further studies are needed to validate this observation, including in non-adenocarcinomatous lung cancers, and to clarify upon the confounding effect of age.     

Secreted Frizzled Related Protein 1 Modulates Taxane Resistance of Human Lung Adenocarcinoma

Taxanes, such as docetaxel and taxol, have been used as firstline chemotherapies in advanced lung adenocarcinoma (LAD), but limited responses to chemotherapy remain a major impediment in the clinic. Treatment with 5-azacytidine increases the sensitivity of SPC-A1/DTX cell line to taxanes. The results of DNA methylation microarray and cDNA array analysis indicate that DNA methylation contributes to the downregulation of secreted frizzled related protein 1 (SFRP1) in SPC-A1/DTX cells. Overexpression of SFRP1 reverses the chemoresistance of taxane-resistant LAD cell lines and enhances the in vivo sensitivity of taxane-resistant LAD cells to taxanes. Meanwhile, short hairpin RNA (shRNA)-mediated SFRP1 knockdown decreases the sensitivity of parental LAD cell lines to taxanes. Furthermore, FH535, a reversible Wnt signaling inhibitor, enhances the sensitivity of taxane-resistant LAD cells to taxanes. The level of SFRP1 in tumors of nonresponding patients is significantly lower than that in tumors of responders. Taken together, our results provide the direct evidence that SFRP1 is a clinically important determinant of taxanes resistance in human LAD cells, suggesting that SFRP1 might be a novel therapeutic target for the treatment of taxane-resistant LAD patients.     

Unique Protein Profiles of Extracellular Vesicles as Diagnostic Biomarkers for Early and Advanced Non‐Small Cell Lung Cancer

Extracellular vesicles (EVs) mediate intercellular communication via transferring proteins and other biological molecules and have been recently investigated as biomarkers of disease. Sensitive and specific biomarkers are required for lung cancer diagnosis and prognosis. The present study screens for abnormal EV proteins in non‐small cell lung cancer (NSCLC) using a quantitative proteomics strategy involving LC‐MS/MS to identify ideal biomarkers for NSCLC diagnosis. EVs are enriched from the sera of early and advanced NSCLC patients and healthy controls and from cell culture supernatants of lung adenocarcinoma and bronchial epithelial cell lines. In the sera and supernatants, 279 and 632 differentially expressed proteins, respectively, are associated with signaling pathways including extracellular membrane–receptor interaction, focal adhesion, and regulation of the actin cytoskeleton. Thirty‐two EV proteins are identified at the intersection of differentially expressed proteins between the NSCLC groups and cell lines. Based on bioinformatics analysis, in silico immunohistochemical, and PRM verification, fibronectin is selected for following in vitro studies and validation with an independent cohort. Fibronectin on EVs is estimated to perform well in the diagnosis of NSCLC patients based on AUC, showing great potential for clinical use and demonstrating the efficacy of this method for EV‐associated biomarker screening.     

应用LCM和蛋白质组学技术筛选肺腺癌的差异表达蛋白质

为筛选肺腺癌(lung adenocarcinoma,AdC)发病相关蛋白质,首先采用激光捕获显微切割技术(laser capture microdissection,LCM)分别从AdC组织和正常支气管上皮(normal bronchial epithelium,NBE)组织中切割并收集AdC细胞和NBE细胞,再应用双向凝胶电泳技术(two-dimensional gel electrophoresis,2-DE)分离经LCM收集的细胞蛋白质,通过PDQuest软件分析差异表达的蛋白质点,基质辅助激光解吸电离飞行时间质谱(MALDI-TOF-MS)鉴定差异表达蛋白质,组织芯片免疫组化方法检测差异蛋白质膜联蛋白A4(annexin A4)在30例AdC组织、配对的癌旁组织和淋巴结转移癌组织中的表达水平。研究结果显示,通过蛋白质组学方法建立了LCM收集的AdC和NBE细胞的2-DE图谱,质谱鉴定得到了33个差异表达蛋白质,其中21个蛋白质在AdC细胞中表达上调,12个蛋白质在AdC细胞中表达下调。组织芯片免疫组化结果显示,与癌旁肺组织相比,annexin A4在AdC组织中的表达水平显著上调,且在AdC淋巴结转移癌组织中的表达明显高于其原发癌组织。上述结果提示annexin A4与AdC的发病及淋巴结转移相关,有望成为诊断AdC及预测AdC转移的分子标志物。     

Gene Expression Profiling in Human Lung Development: An Abundant Resource for Lung Adenocarcinoma Prognosis

A tumor can be viewed as a special “organ” that undergoes aberrant and poorly regulated organogenesis. Progress in cancer prognosis and therapy might be facilitated by re-examining distinctive processes that operate during normal development, to elucidate the intrinsic features of cancer that are significantly obscured by its heterogeneity. The global gene expression signatures of 44 human lung tissues at four development stages from Asian descent and 69 lung adenocarcinoma (ADC) tissue samples from ethnic Chinese patients were profiled using microarrays. All of the genes were classified into 27 distinct groups based on their expression patterns (named as PTN1 to PTN27) during the developmental process. In lung ADC, genes whose expression levels decreased steadily during lung development (genes in PTN1) generally had their expression reactivated, while those with uniformly increasing expression levels (genes in PTN27) had their expression suppressed. The genes in PTN1 contain many n-gene signatures that are of prognostic value for lung ADC. The prognostic relevance of a 12-gene demonstrator for patient survival was characterized in five cohorts of healthy and ADC patients [ADC_CICAMS (n = 69, p = 0.007), ADC_PNAS (n = 125, p = 0.0063), ADC_GSE13213 (n = 117, p = 0.0027), ADC_GSE8894 (n = 62, p = 0.01), and ADC_NCI (n = 282, p = 0.045)] and in four groups of stage I patients [ADC_CICAMS (n = 22, p = 0.017), ADC_PNAS (n = 76, p = 0.018), ADC_GSE13213 (n = 79, p = 0.02), and ADC_qPCR (n = 62, p = 0.006)]. In conclusion, by comparison of gene expression profiles during human lung developmental process and lung ADC progression, we revealed that the genes with a uniformly decreasing expression pattern during lung development are of enormous prognostic value for lung ADC.     

Lead Dysregulates Serine/Threonine Protein Phosphatases in Human Neurons

It is well established that lead (Pb) exposure in humans leads to learning and memory impairment. However, the biological and molecular mechanisms are still not clearly understood. When over activated, serine/threonine protein phosphatases are known to function as a constraint on learning and memory. Activation of these phosphatases can also result in cytoskeletal changes that will adversely affect learning and memory. We investigated the effects of Pb exposure on these phosphatases in primary cultures of human neurons. Neurons were exposed to physiologically relevant concentrations of Pb (5, 10, 20 and 40 μg/dL) and total phosphatase and PP2A activities were determined in neuronal lysate using para-nitrophenyl phosphate (pNPP), and a PP2A-specific phosphopeptide as substrates. Expression of various serine/threonine phosphatases, tau and its phosphorylation state were determined by Western blot (WB) and immunocytochemistry (ICC). We found that the total phosphatase activity in the neuronal lysate was increased by 30–50% by all the concentrations of Pb tested. PP2A activity was increased by 5 μg/dL Pb only. PP1 expression was increased (ranging from 25–50%) by 10, 20 and 40 μg/dL of Pb. PP2B expression was increased substantially (up to 2.5-fold) by 10 μg/dL Pb, whereas, higher concentrations did not show any effect. On the other hand, Pb (at all concentrations used) decreased expression of PP2A and PP5. Pb exposure induced substantial hyperphosphorylation of tau at serine 199/202 by 5 and 10 μg/dL Pb, and Threonine 231 at higher doses. Expression of total tau was mostly unaffected by lead. Immunocytochemistry data confirmed the WB results of expression of PP1, PP2A, tau protein and the phosphorylation of tau. These results support our hypothesis that Pb exposure up regulates some of the serine/threonine phosphatases (PP1 and PP2B) that are known to impair memory formation, and suggest a novel mechanism of Pb neurotoxicity.     

普萘洛尔对映异构体诱导HUVEC细胞的蛋白质表达谱差异

手性药物只能通过严格的手性识别才能选择性地与特定生物大分子相互作用,在药动学、药效学等方面上表现出手性特征.以非选择性β肾上腺素能受体阻滞剂普萘洛尔（PRO）的对映异构体R(+)/S(-)-PRO为模型药物,分别作用于人脐静脉内皮细胞（HUVEC）,提取全细胞蛋白质,经双向电泳、MALDI-TOF-MS、SWISSPROT数据库分析鉴定差异表达蛋白质;共筛选出22个差异表达蛋白质点,鉴定了HSP86、HSP84、GRP75、KLC18、KBTB2、TGM2、GBLP、GCNT2、RAB36、KLH34等10种蛋白质.研究表明,PRO对映异构体可引起广泛的基因表达改变,涉及信号分子、代谢酶、骨架蛋白、伴侣蛋白等,且具有显著的手性特征,这可能与PRO显著的手性生物学特征有紧密联系,但仍需开展进一步深入研究,以明确产生PRO手性生物学特征的多种途径和机制.蛋白质组学技术为深入了解药物的手性生物学特征及其作用机制提供了新的思路和策略,对手性药物开发和临床合理用药有着重要的意义.     

蛋白酪氨酸激酶抑制剂Genistein抑制肺癌细胞A549体外侵袭作用的研究

观察蛋白酪氨酸激酶抑制剂Genistein对人肺腺癌细胞株A549细胞侵袭能力的影响,探讨Genistein抑制肺癌细胞侵袭的可能机制。以不同浓度Genistein（20μmol/L和40μmol/L）作用于A549细胞3 d后,分别用基质胶侵袭模型、黏附基质分析、Transwell小室趋化运动模型、细胞骨架蛋白染色及RT-PCR法来研究药物处理后细胞侵袭、黏附、运动、聚合型骨架蛋白（F-actin）以及基质金属蛋白酶基因表达的改变。经Genistein处理后,A549细胞的F-actin聚合减少,侵袭能力明显下降,趋化运动能力降低,基质金属蛋白酶抑制剂（TIMP-1）基因相对表达量增加,但黏附率没有降低。Genistein可降低肺癌细胞的迁移、侵袭能力。F-actin聚合减少,TIMP-1的相对表达量增加,可能是Genistein抑制肺癌细胞侵袭的机制之一。     

转基因人肺腺癌细胞株的建立

以逆转录病毒ｐＬＸＳＬ为载体与人细胞介素２基因（ＩＬ－２）重组,用电穿孔技术将其重组子ｐＬＩＬ—２ＳＮ导入ＰＡ３１７细胞中,建立了逆转染病毒包装体系细胞ＰＡ３１７／ｐＬＩＬ—２ＳＮ。应用逆转录病毒包装体系细胞上清液去转染入肺腺癌细胞ＳＰＣ—Ａ１,经过２０天含Ｇ４１８培液的筛选式培养,历经了５０代的传代培养,获得了转白细胞介素２基因的人肺腺癌细胞株ＳＰＣ－Ａ１／ＩＬ－２。该细胞（ＳＰＣ－Ａ１／ＩＬ－２）经ＰＣＲ技术验证外源性目的基因（ＩＬ－２ｇｅｎｅ）导入细胞内,且证明该细胞能表达ＩＬ—２基因（有ＩＬ－２的分泌）。我们研究的目的是对肿瘤细胞的特异性抗原修饰、对肿瘤细胞进行处理。试图建立肿瘤疫苗。     

人肺腺癌细胞系cDNA文库的建立

本文以Uni-ZAP XR为载体,成功地建立了人肺腺癌高、低转移细胞系的cDNA文库。文中同时也探讨了总RNA的提取和mRNA的分离,cDNA的第一条链及第二条链的合成及克隆到载体等在建立cDNA文库过程中,几个关键性的问题。该项工作的完成,为下一步在这两株细胞系cDNA之间进行消减式杂交,筛选转移相关基因奠定了坚实基础。     

澳洲茄边碱通过Caspase3蛋白诱导人肺腺癌A549细胞的凋亡作用

运用中药龙葵提取物澳洲茄边碱处理人肺腺癌A549细胞,研究其对A549细胞的抑制及凋亡作用,探讨澳洲茄边碱对肺腺癌的作用机制。通过细胞增殖抑制实验检测不同浓度澳洲茄边碱对A549细胞增殖的影响,采用蛋白印迹法(Western blot)检测凋亡蛋白Caspase3的表达水平,采用流式细胞术测定处理后A549细胞的凋亡水平及细胞周期变化。结果显示,不同浓度澳洲茄边碱均能抑制A549的增殖,呈浓度效应;用不同浓度澳洲茄边碱处理A549细胞24h后,Western blot结果显示,随药物浓度增大,凋亡蛋白Caspase3水解程度增高,对A549凋亡作用明显增强;流式细胞术检测细胞凋亡的结果显示,20μmol·L-1澳洲茄边碱处理A549细胞后,细胞发生明显凋亡,其中早期凋亡细胞比例为25.35%,晚期凋亡细胞比例为11.47%;流式细胞术检测细胞周期的结果显示,20μmol·L-1澳洲茄边碱处理A549细胞后,细胞周期阻滞于G2/M期。本研究结果表明,澳洲茄边碱通过激活细胞凋亡通路中的Caspase3蛋白触发细胞凋亡,同时将A549细胞阻滞在细胞周期的G2/M期,抑制人肺腺癌细胞A549的生长。     

大鼠不同发育时期胰腺相关蛋白的差异表达

探讨大鼠胰腺不同发育时期相关蛋白的差异表达,应用显微技术分离了大鼠孕15.5天,孕18.5天胚胎胰腺和新生鼠及成年鼠的胰腺,提取其蛋白质后,用固相pH梯度双向聚丙烯酰胺凝胶电泳和质谱分析等蛋白质组学方法,得到了4个不同发育时期的蛋白质表达谱.对其中的6个在孕18.5天胚胎胰腺中有高丰度表达,而在成年鼠胰腺中缺失的蛋白质点,4个在成年胰腺中特异表达的蛋白质点, 8个在成年胰腺中表达明显下调的蛋白质点和1个在成年中表达上调的点,进行了肽质量指纹分析和蛋白质鉴定,共获得18个点的肽质量指纹图.经BIOWORK等软件搜索大鼠非冗余蛋白质数据库来鉴定其身份,发现其中7个点为大鼠甲胎蛋白（AFP）、5个点为胰脂酶相关蛋白1前体、1个点为微管蛋白β、2个点为蛋白二硫异构酶、1个为FLN29基因产物的类似物、1个为胰蛋白酶V-A前体、1个为过氧化物氧化还原酶4.其中AFP为特异表达于大鼠胚胎期及新生期胰腺的蛋白质,在孕18.5天的胰腺中表达量最高,在成年胰腺中极低表达.对它们的功能和与胚胎胰腺代谢调节功能完善过程的可能关系进行了初步探讨.     

人原发性肺腺癌转移相关分子的定量蛋白质组学研究

癌细胞转移是人原发性肺腺癌(lung adenocarcinoma, AdC)死亡率高和预后差的主要原因．为了筛选潜在的肺腺癌转移相关分子标志物,依据临床诊断选取无转移的肺腺癌组织和有转移的肺腺癌组织作为研究对象,首先采用激光捕获显微切割技术(laser capture microdissection, LCM)对两组肺腺癌组织中的癌细胞进行纯化,再利用荧光差异凝胶电泳技术(two-dimensional differential in-gel electrophoresis, 2D-DIGE)分离无转移肺腺癌组和有转移肺腺癌组的癌细胞总蛋白,通过Decyder软件分析两组差异表达的蛋白质点,质谱(mass spectrometry, MS)对差异表达的蛋白质点进行鉴定,Western blot验证部分差异蛋白annexin A1, annexin A2, annexin A3, B23和 S100A9的表达．建立了LCM 纯化的无转移和有转移的肺腺癌组织癌细胞的2D-DIGE图谱,质谱鉴定了20个非冗余差异蛋白质,其中12个蛋白质在有转移肺腺癌组中较无转移肺腺癌组表达上调,8个蛋白质在有转移肺腺癌组中表达下调．Western blot验证分析显示,差异蛋白annexin A1,annexin A2,annexin A3和 S100A9的表达水平在有转移肺腺癌中较无转移肺腺癌增高,B23的表达水平在有转移肺腺癌中较无转移肺腺癌降低．免疫组化进一步证实S100A9在有转移的肺腺癌中较无转移的肺腺癌中表达上调．首次应用LCM技术联合2D-DIGE及MS技术分析鉴定出肺腺癌转移相关蛋白质,为研究肺腺癌的转移分子机制、筛选预测肺腺癌转移的分子标志物奠定了基础．     

外源上皮钙粘着蛋白基因在人肺腺癌细胞中的表达及调节细胞悬浮生长

为了研究上皮钙粘着蛋白（E-cadherin)对人肺腺癌细胞间粘聚和细胞悬浮生长的影响。利用基因重组技术构建了含全长上皮钙粘着蛋白cDNA的真核表达载体。通过脂质体法转染到A549肺腺癌细胞株中,用RT-PCR和Western印迹鉴定并筛选上皮钙粘着蛋白高表达的细胞,株,并观察转染前后肿瘤细胞间粘聚能力的改变以及细胞悬浮培养下的生长状态,结果表明转染细胞间聚集力比对照细胞增强,上皮钙粘着蛋白能够促进细胞悬浮生长的速度。     

双水相纯化的人肺腺癌和癌旁正常肺组织质膜蛋白质组差异分析

肿瘤标志物对于肺腺癌病人的临床诊断和预后具有重要意义. 本研究根据临床诊断选取人肺腺癌组织和癌旁正常肺组织为研究对象,采用差速离心联合双水相法纯化组织细胞质膜,运用同位素标记相对和绝对定量技术结合高效液相色谱 串联质谱技术,鉴定出肺腺癌组织和癌旁正常肺组织的差异蛋白质41种. 同癌旁正常肺组织相比,18个蛋白质在肺腺癌组织中表达上调,23个蛋白质在肺腺癌组织中表达下调. 生物信息学分析发现,差异质膜蛋白质FLOT1、CAV1和ITGB1均处于蛋白质相互作用网络的重要位置,可能参与了肺腺癌相关信号转导.利用蛋白质印迹和免疫组织化学染色验证,差异蛋白质FLOT1、CAV1和ITGB1在肺腺癌织和癌旁正常肺组织的表达情况,其验证结果与蛋白质组学研究结果一致. 研究结果对肺腺癌诊断标志物和肺腺癌癌变分子机理研究具有重要意义.     

激光捕获显微切割在肿瘤多组学研究中的应用进展

当今社会,肿瘤因其高发病率和高死亡率成为威胁人类健康的重要疾病,研究者们对其发病机制及治疗手段的研究和探索也在不断深入。随着单细胞多组学测序技术的发展,肿瘤组织的异质性问题逐渐被研究人员所认识。为了解决这一问题,激光捕获显微切割（laser capture microdissection,LCM）技术应运而生。LCM技术是一种在显微镜直视下从器官或组织中准确获取某种特定的细胞群或单个细胞的样本收集技术。LCM技术结合多种分子生物学手段可以对异质性组织进行多组学研究,丰富了现有的肿瘤蛋白质组学、基因组学以及转录组学图谱,因此,LCM技术成为研究特异性表达及分子机制的有力工具,在肿瘤学领域得到广泛应用。基于此,对LCM的原理、优势及其在肿瘤多组学研究中的应用进行了综述,并对其未来可能的发展方向进行了展望,以期为肿瘤的研究和治疗提供新的思路。     

Erythropoietin Receptor Expression Is a Potential Prognostic Factor in Human Lung Adenocarcinoma

Recombinant human erythropoietins (rHuEPOs) are used to treat cancer-related anemia. Recent preclinical studies and clinical trials, however, have raised concerns about the potential tumor-promoting effects of these drugs. Because the clinical significance of erythropoietin receptor (EPOR) signaling in human non-small cell lung cancer (NSCLC) also remains controversial, our aim was to study whether EPO treatment modifies tumor growth and if EPOR expression has an impact on the clinical behavior of this malignancy. A total of 43 patients with stage III–IV adenocarcinoma (ADC) and complete clinicopathological data were included. EPOR expression in human ADC samples and cell lines was measured by quantitative real-time polymerase chain reaction. Effects of exogenous rHuEPOα were studied on human lung ADC cell lines in vitro. In vivo growth of human ADC xenografts treated with rHuEPOα with or without chemotherapy was also assessed. In vivo tumor and endothelial cell (EC) proliferation was determined by 5-bromo-2’-deoxy-uridine (BrdU) incorporation and immunofluorescent labeling. Although EPOR mRNA was expressed in all of the three investigated ADC cell lines, rHuEPOα treatment (either alone or in combination with gemcitabine) did not alter ADC cell proliferation in vitro. However, rHuEPOα significantly decreased tumor cell proliferation and growth of human H1975 lung ADC xenografts. At the same time, rHuEPOα treatment of H1975 tumors resulted in accelerated tumor endothelial cell proliferation. Moreover, in patients with advanced stage lung ADC, high intratumoral EPOR mRNA levels were associated with significantly increased overall survival. This study reveals high EPOR level as a potential novel positive prognostic marker in human lung ADC.     

Olfactory Neurons Obtained through Nasal Biopsy Combined with Laser-Capture Microdissection: A Potential Approach to Study Treatment Response in Mental Disorders

Bipolar disorder (BD) is a severe neuropsychiatric disorder with poorly understood pathophysiology and typically treated with the mood stabilizer, lithium carbonate. Animal studies as well as human genetic studies indicate that lithium affects molecular targets that are involved in neuronal growth, survival and maturation, and notably molecules involved in Wnt signaling. Given the ethical challenge to obtaining brain biopsies for investigating dynamic molecular changes associated with lithium-response in the central nervous system (CNS), one may consider the use of neurons obtained from olfactory tissues to achieve this goal.The olfactory epithelium contains olfactory receptor neurons at different stages of development and glial-like supporting cells. This provides a unique opportunity to study dynamic changes in the CNS of patients with neuropsychiatric diseases, using olfactory tissue safely obtained from nasal biopsies. To overcome the drawback posed by substantial contamination of biopsied olfactory tissue with non-neuronal cells, a novel approach to obtain enriched neuronal cell populations was developed by combining nasal biopsies with laser-capture microdissection. In this study, a system for investigating treatment-associated dynamic molecular changes in neuronal tissue was developed and validated, using a small pilot sample of BD patients recruited for the study of the molecular mechanisms of lithium treatment response.